{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:49:26Z","timestamp":1794268166519,"version":"4.9.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Analysis of intraclonal heterogeneity has yielded insights into the clonal evolution of hematologic malignancies. We compared the clonal and subclonal compositions of the underlying plasma cell dyscrasia in 544 systemic light chain amyloidosis (PC-AL) patients with 519 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or symptomatic MM; ie, PC\u2013non-AL patients). Using interphase fluorescence in situ hybridization, subclones were stringently defined as clone size below two thirds of the largest clone and an absolute difference of \u226530%. Subclones were found less frequently in the PC-AL group, at 199 (36.6%) of 544 as compared with 267 (51.4%) of 519 in the PC\u2013non-AL group (P &amp;lt; .001), and were not associated with the stage of plasma cell dyscrasia in either entity. In both groups, translocation t(11;14), other immunoglobulin heavy chain translocations, and hyperdiploidy were typically found as main clones, whereas gain of 1q21 and deletions of 8p21, 13q14, and 17p13 were frequently found as subclones. There were no shifts in the subclone\/main clone ratio depending on the MGUS, SMM, or MM stage of plasma cell dyscrasia. In multivariate analysis, t(11;14) was associated with lower rates of subclone formation and hyperdiploidy with higher rates. PC-AL itself lost statistical significance, demonstrating that the lower subclone frequency in AL is a reflection of its exceptionally high t(11;14) frequency. In summary, the subclone patterns in PC-AL and PC\u2013non-AL are closely related, implying that subclone formation depends on the main cytogenetic categories and is independent of disease entity and stage.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018023200","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T15:55:27Z","timestamp":1539705327000},"page":"2607-2618","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma"],"prefix":"10.1182","volume":"2","author":[{"given":"Tilmann","family":"Bochtler","sequence":"first","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"Clinical Cooperation Unit, Molecular Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Granzow","sequence":"additional","affiliation":[{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin","family":"Kr\u00e4mer","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Clinical Cooperation Unit, Molecular Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Steffen","family":"Raab","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Department of Medicine, Roswell Park Cancer Institute, Buffalo NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kimmich","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Dittrich","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"Clinical Cooperation Unit, Molecular Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"},{"name":"Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nland","sequence":"additional","affiliation":[{"name":"Department of Medicine V, Hematology\/Oncology\/Rheumatology, University of Heidelberg, Heidelberg, Germany;"},{"name":"Amyloidosis Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"issue":"7330","key":"2020021108380580000_B1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"},{"key":"2020021108380580000_B2","doi-asserted-by":"crossref","first-page":"h6581","DOI":"10.1136\/bmj.h6581","article-title":"Cancer\u2019s Darwinian dilemma: an evolutionary tale in three acts","volume":"351","author":"Greaves","year":"2015","journal-title":"BMJ"},{"issue":"7382","key":"2020021108380580000_B3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"31","key":"2020021108380580000_B4","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2013.50.7921","article-title":"Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia","volume":"31","author":"Bochtler","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021108380580000_B5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-03-412981","article-title":"Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma","volume":"120","author":"Walker","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2020021108380580000_B6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2020021108380580000_B7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2020021108380580000_B8","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"2020021108380580000_B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"2020021108380580000_B10","doi-asserted-by":"crossref","first-page":"232546","DOI":"10.1155\/2014\/232546","article-title":"Implications of heterogeneity in multiple myeloma","volume":"2014","author":"de Mel","year":"2014","journal-title":"BioMed Res Int"},{"issue":"9","key":"2020021108380580000_B11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-14-2576","article-title":"The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma","volume":"21","author":"An","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2020021108380580000_B12","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.clml.2016.02.025","article-title":"Clonal evolution in multiple myeloma","volume":"16","author":"Fakhri","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2020021108380580000_B13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bjh.14649","article-title":"Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma","volume":"178","author":"Dutta","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2020021108380580000_B14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"2020021108380580000_B15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.gde.2015.03.008","article-title":"Genomic heterogeneity in multiple myeloma [published correction appears in Curr Opin Genet Dev. 2016;37:158","volume":"30","author":"Szalat","year":"2015","journal-title":"Curr Opin Genet Dev"},{"issue":"7","key":"2020021108380580000_B16","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","article-title":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis","volume":"98","author":"Hayman","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2020021108380580000_B17","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2007-11-122101","article-title":"Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability","volume":"111","author":"Bochtler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2020021108380580000_B18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"issue":"14","key":"2020021108380580000_B19","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2020021108380580000_B20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3324\/haematol.2016.160721","article-title":"Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis","volume":"102","author":"Granzow","year":"2017","journal-title":"Haematologica"},{"key":"2020021108380580000_B21","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1038\/bcj.2015.34","article-title":"Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death","volume":"5","author":"Warsame","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"2020021108380580000_B22","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"2020021108380580000_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","article-title":"Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma","volume":"2","author":"Merz","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"2020021108380580000_B24","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"34","key":"2020021108380580000_B25","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020021108380580000_B26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"2020021108380580000_B27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"2020021108380580000_B28","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2020021108380580000_B29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2020021108380580000_B30","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2020021108380580000_B31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020021108380580000_B32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"},{"issue":"11","key":"2020021108380580000_B33","doi-asserted-by":"crossref","first-page":"e0188274","DOI":"10.1371\/journal.pone.0188274","article-title":"Clustering of samples and variables with mixed-type data","volume":"12","author":"Hummel","year":"2017","journal-title":"PLoS One"},{"issue":"26","key":"2020021108380580000_B34","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of multiple myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2020021108380580000_B35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13039-017-0327-3","article-title":"Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma","volume":"10","author":"Smol","year":"2017","journal-title":"Mol Cytogenet"},{"issue":"1","key":"2020021108380580000_B36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"2020021108380580000_B37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/157339471002141124121404","article-title":"Biological and clinical implications of clonal heterogeneity and clonal evolution in multiple myeloma","volume":"10","author":"Bianchi","year":"2014","journal-title":"Curr Cancer Ther Rev"},{"issue":"12","key":"2020021108380580000_B38","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021108380580000_B39","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/20\/2607\/1629522\/advances023200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/20\/2607\/1629522\/advances023200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:10:10Z","timestamp":1581430210000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/20\/2607\/16105\/Cytogenetic-intraclonal-heterogeneity-of-plasma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":39,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2018,10,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018023200","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]}}}